Avadel Pharmaceuticals PLC (AVDL) Stock

DelistedNasdaq: AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.

21.63
Final close · Feb 10, 2026

AVDL is no longer traded. Avadel Pharmaceuticals was acquired by Alkermes (ALKS) on February 12, 2026.

Each AVDL share was exchanged for $21.00 in cash plus a contingent value right of $1.50. Prices on this page are historical; the last trade was February 10, 2026 at $21.63.

See Alkermes (ALKS) stock →

Avadel Pharmaceuticals stock price history

Split-adjusted closes, 1996–2026

AVDL final trading statistics

Final close
$21.63
Final trading day
Feb 10, 2026
Market cap at delisting
$2.12B
Shares outstanding
98.15M
Final 52-week range
$6.38 – $23.57
Avg. volume (final 3 mo.)
1,912,646
All-time high (split-adj.)
$42.85 · Sep 2003
All-time low (split-adj.)
$0.94 · Oct 2001
Return since IPO
+84.1%
Beta
1.63
Book value / share
$1.01
Price / book
21.42
Final 52 wk
6.3823.57

Avadel Pharmaceuticals earnings per share

Earnings per share

Avadel Pharmaceuticals revenue & net income

RevenueNet income

Avadel Pharmaceuticals annual financials

Fiscal yearRevenueNet incomeEPS
FY2024$169.12M-$48.8M-$0.52
FY2023$27.96M-$160.3M-$2.01
FY2022$1.50M-$137.5M-$2.25
FY2021$0.00-$77.3M-$1.32
FY2020$22.33M$7.0M-$0.56

Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.

Avadel Pharmaceuticals stock FAQ

What happened to Avadel Pharmaceuticals stock?

Avadel Pharmaceuticals was acquired by Alkermes (ALKS) on February 12, 2026. Shareholders received $21.00 in cash plus a contingent value right of $1.50 for each share. AVDL stock stopped trading on the Nasdaq, with a final close of $21.63 on February 10, 2026.

What did Avadel Pharmaceuticals shareholders receive?

Each AVDL share was converted into $21.00 in cash plus a contingent value right of $1.50.

Is AVDL stock still trading?

No. AVDL was delisted from the Nasdaq on February 12, 2026 and no longer trades on a U.S. exchange.

What was the last price of AVDL stock?

AVDL closed at $21.63 on its final trading day, February 10, 2026, for a market value of about $2.12B.

What were Avadel Pharmaceuticals's revenue and earnings in its last full fiscal year?

Avadel Pharmaceuticals reported revenue of $169.12M and net income of -$48.8M in fiscal 2024, its last full year as a public company.

When did Avadel Pharmaceuticals go public?

Avadel Pharmaceuticals PLC stock began trading on June 7, 1996.

Drug Manufacturers - Specialty & Generic stocks to research

All Healthcare stocks →